購物車 
-
克拉夫定
- names：
Clevudine
- CAS號：
163252-36-6
MDL Number： MFCD00935785 - MF(分子式)： C10H13FN2O5 MW(分子量)： 260.22
- EINECS: Reaxys Number:
- Pubchem ID:73115 Brand:BIOFOUNT
克拉夫定(Clevudine,163252-36-6)是一種合成的嘧啶類似物，對乙型肝炎病毒（HBV）具有活性。 在細胞內，克列夫定被磷酸化為其活性代謝產物，克拉夫定單磷酸鹽和三磷酸鹽。 三磷酸代謝物與胸苷競爭并入病毒DNA中，從而導致DNA鏈終止并抑制HBV DNA聚合酶（逆轉錄酶）的功能。 克拉夫定具有長的半衰期，并且顯示出共價閉合的環狀DNA（cccDNA）的顯著減少.
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000536-50mg | 50mg | 99.95% | ￥ 6874.00 | ￥ 6874.00 | 2-3天 | ￥ 0.00 | ||
| YZM000536-10mg | 10mg | 99.95% | ￥ 2184.00 | ￥ 2184.00 | 2-3天 | ￥ 0.00 |
| 中文別名 | 克拉夫定(cas:163252-36-6),1-(2'-脫氧-2'-氟-L-阿拉伯呋喃糖基)-5-甲基尿嘧啶 |
| 英文別名 | Clevudine(cas:163252-36-6),Levovir,L-FMAU,Clevudine (Levovir) |
| CAS號 | 163252-36-6 |
| Inchi | InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1 |
| InchiKey | GBBJCSTXCAQSSJ-XQXXSGGOSA-N |
| 分子式 Formula | C10H13FN2O5 |
| 分子量 Molecular Weight | 260.22 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 50 mg/mL(192.15 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 固體粉末,Power |
| 儲藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Clevudine(CAS:163252-36-6)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:克拉夫定蒸汽壓,克拉夫定合成,克拉夫定標準,克拉夫定應用,克拉夫定合成,克拉夫定沸點,克拉夫定閃點,克拉夫定用途,克拉夫定溶解度,克拉夫定價格,克拉夫定作用,克拉夫定結構式,克拉夫定用處
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:克拉夫定蒸汽壓,克拉夫定合成,克拉夫定標準,克拉夫定應用,克拉夫定合成,克拉夫定沸點,克拉夫定閃點,克拉夫定用途,克拉夫定溶解度,克拉夫定價格,克拉夫定作用,克拉夫定結構式,克拉夫定用處
| 產品說明 | 克拉夫定(Clevudine,163252-36-6)是嘧啶2'-脫氧核糖核苷。克拉夫定溶解度,克拉夫定MSDS詳見主頁。 |
| Introduction | Clevudine (克拉夫定,163252-36-6)is a pyrimidine 2'-deoxyribonucleoside. |
| Application1 | udine是一種合成的嘧啶類似物，對乙型肝炎病毒（HBV）具有活性。 在細胞內，克列夫定被磷酸化為其活性代謝產物，克列夫定單磷酸鹽和三磷酸鹽。 |
| Application2 | 克列夫定具有長的半衰期 |
| Application3 |
克拉夫定(Clevudine,163252-36-6)brief：
Clevudine is a synthetic pyrimidine analogue with activity against hepatitis B virus (HBV). Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase (reverse transcriptase). Clevudine has a long half-life and shows significant reduction of covalently closed circular DNA (cccDNA)
Clevudine is a synthetic pyrimidine analogue with activity against hepatitis B virus (HBV). Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase (reverse transcriptase). Clevudine has a long half-life and shows significant reduction of covalently closed circular DNA (cccDNA)
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護 | P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理 |
| 備注 | 實驗過程中防止吸入、食入，做好安全防護 |
| Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy Journal of Gastroenterology 2010 |
| A comparison of clevudine and entecavir for treatment-na?ve patients with chronic hepatitis B: results after 2 years of treatment Hepatology International 2012 |
| A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-na?ve patients with chronic hepatitis B Hepatology International 2010 |
| Monofluorinated Heterocycles Halogenated Heterocycles 2011 |
| 2013-09-01 Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine Antimicrobial agents and chemotherapy |
其他文獻：
1. 2013-09-01 Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine Antimicrobial agents and chemotherapy
2. 2012-10-01 Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([18F]-FMAU) Nuclear medicine and biology
3. 2012-09-01 [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations Molecular imaging
4. 2012-04-01 Simultaneous determination of 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
5. 2012-04-01 [New drugs of treatment of patients with chronic hepatitis B] Nihon rinsho. Japanese journal of clinical medicine
1. 2013-09-01 Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine Antimicrobial agents and chemotherapy
2. 2012-10-01 Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([18F]-FMAU) Nuclear medicine and biology
3. 2012-09-01 [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations Molecular imaging
4. 2012-04-01 Simultaneous determination of 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
5. 2012-04-01 [New drugs of treatment of patients with chronic hepatitis B] Nihon rinsho. Japanese journal of clinical medicine
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
